Product
Emapalumab-Lzsg
Aliases
Emapalumab-Lzsg 5 MG/ML [Gamifant], Gamifant
Name
GAMIFANT
INN Name
emapalumab-lzsg
FDA Approved
Yes
2 clinical trials
1 organization
2 indications
1 document
Indication
Hemophagocytic LymphohistiocytosisIndication
Hemophagocytic LymphohistiocytosesClinical trial
An Open Label, Single Arm, Multi-Centre, Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of Primary Hemophagocytic Lymphohistiocytosis in Treatment Experienced Chinese PatientsStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
A Phase 2/3, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Emapalumab in Adult Patients With Hemophagocytic LymphohistiocytosisStatus: Terminated, Estimated PCD: 2021-06-29
Document
DailyMed Label: GAMIFANTOrganization
SWEDISH ORPHAN BIOVITRUM AB (PUBL)